Disease overview Chronic lymphocytic leukemia (CLL) is one of the most frequent types of
leukemia. It typically occurs in elderly patients and has a highly variable clinical course …

The introduction of anti-CD20 monoclonal antibodies such as rituximab, ofatumumab, or
obinutuzumab improved the therapy of B-cell malignancies even though the precise …

Recent advances in cancer characterization have consistently revealed marked
heterogeneity, impeding the completion of integrated molecular and clinical maps for each …

Background Venetoclax inhibits BCL2, an antiapoptotic protein that is pathologically
overexpressed and that is central to the survival of chronic lymphocytic leukemia cells. We …

Bruton's tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic
signaling that is critical for proliferation and survival of leukemic cells in many B cell …

Important advances in understanding the pathogenesis of chronic lymphocytic leukaemia in
the past two decades have led to the development of new prognostic tools and novel …

Despite promising results with targeted drugs, chemoimmunotherapy with fludarabine,
cyclophosphamide (FC), and rituximab (R) remains the standard therapy for fit patients with …

Abstract Disease Overview Chronic lymphocytic leukemia (CLL) is the commonest leukemia
in western countries. The disease typically occurs in elderly patients and has a highly …

Ibrutinib, an oral covalent inhibitor of Bruton's tyrosine kinase, is an effective therapy for
patients with chronic lymphocytic leukemia (CLL). To determine whether rituximab provides …

During the past decades, anticancer immunotherapy has evolved from a promising
therapeutic option to a robust clinical reality. Many immunotherapeutic regimens are now …